Molecular Oncology
Analysis of BRCA1 and BRCA2 genes for screening against the risk of breast and ovarian cancer
Cancer is a serious illness due to the mutation of some genes. These mutations induce cells to grow uncontrolled and anomalously. Breast cancer is the most common type of tumor in the world in women while ovarian cancer is the fifth most common tumor in Europe. About 10% of breast tumors and 15% of ovarian tumors are hereditary.
The mutations of the BRCA1 and BRCA2 genes are the most significant risk factors for breast and ovarian cancer.
Congenital mutations in the BRCA1 and BRCA2 genes represent the most common cause of hereditary breast cancer, and contribute to increasing the risk of developing other tumors in both men and women. Damaging mutations in BRCA genes can cause breast or ovarian cancer and an early debut, even before the age of 30. The first degree relatives of a bearer of a mutation of the BRCA genes have a much higher risk of developing a tumor.
Each son of a parent with a mutation of the BRCA genes has a 50% probability of inheriting this mutation. The presence of a family member within 40 years suffering from breast cancer increases the risk for the rest of the family. About 50% of women with BRCA1 or BRCA2 mutations do not have a family history of breast or ovarian cancer, therefore, they are not aware of the mutations that cause cancer.
Genechron offers preventive, quick and safe screening with clear and fast results
The survival rate for breast and ovarian cancer grows significantly when discovered at an initial stage, when there are greater possibility of treatment. The lack of signals and symptoms in the initial phase leads to a late diagnosis connected to low survival rates. The current standard procedures are able to detect only the changes already present in the fabric, a symptom of an already started tumor progression. The early detection and precise identification of the mutations of the BRCA1 and BRCA2 genes can make the difference.
The screening of BRCA 1 and 2 genes can save life because it is able to identify in advance the bearers of any mutations, and allows you to implement preventive treatments, just when these are more effective.
The test proposed by Genechron is able to provide precise and reliable results of the analysis of the genes BRCA 1 and BRCA2 in about 1 month from the reception of the sample in the laboratory.
Our test is:
- Easy: the DNA sample needed to analysis is collected through a buccal swab that is neither invasive nor painful
- Accurate: complete sequencing of the BRCA1 and BRCA2 genes. Detection of all pathogenetic mutations
- Precocious: women of all ages can be eligible for this screening test – early detection allows a more effective preventive action for their well -being
- Reliable: the test is marked CE-IVD and provides a result with high sensitivity
Genechron S.r.l. offers a service that also includes the complete sequencing of the coding regions and the mutional analysis of the following genes: TP53, RET, MSH2/MLH1, CDKN2A. Furthermore, the analysis of the V617F mutation of the JAK2 gene can also be requested.
Analysis included in the package:
Complete Package – Breast and ovarian cancer prevention
Package dedicated to women who wish to know the status of their genetic predisposition to the development of breast and ovarian cancer. The package includes the molecular analysis of the BRCA1 and BRCA2 genes and a genetic consultancy service with one of our expert geneticists.
From Research to Advanced Health Care Diagnostics
CONTACT US WITHOUT COMMITMENT WITH THE METHOD YOU PREFER
+39.06.5036729
info@genechron.com
